Randomization to omega-3 fatty acid supplementation (eicosapentaenoic acid dose range, 226-1800 mg/d) had no significant associations with coronary heart disease death (rate ratio [RR], 0.93; 99% CI, 0.83-1.03; P = .05), nonfatal myocardial infarction (RR, 0.97; 99% CI, 0.87-1.08; P = .43) or any coronary heart disease events (RR, 0.96; 95% CI, 0.90-1.01; P = .12). Neither did randomization to omega-3 fatty acid supplementation have any significant associations with major vascular events (RR, 0.97; 95% CI, 0.93-1.01; P = .10), overall or in any subgroups, including subgroups composed of persons with prior coronary heart disease, diabetes, lipid levels greater than a given cutoff level, or statin use.
---
Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks
Meta-analysis of 10 Trials Involving 77 917 Individuals
JAMA Cardiol. 2018;3(3):225-234.
[Ссылки доступны только зарегистрированным пользователям ]
__________________
Искренне,
Вадим Валерьевич.
|